Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/173947
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Fuente, José de la | - |
dc.contributor.author | Gortázar, Christian | - |
dc.contributor.author | Juste, Ramón A. | - |
dc.date.accessioned | 2019-01-11T09:58:34Z | - |
dc.date.available | 2019-01-11T09:58:34Z | - |
dc.date.issued | 2016 | - |
dc.identifier | doi: 10.1586/14760584.2016.1125294 | - |
dc.identifier | e-issn: 1744-8395 | - |
dc.identifier | issn: 1476-0584 | - |
dc.identifier.citation | Expert Review of Vaccines 15(3): 275-277 (2016) | - |
dc.identifier.uri | http://hdl.handle.net/10261/173947 | - |
dc.description.abstract | Vaccines are critical for the control of tuberculosis (TB) affecting humans and animals worldwide. First-generation vaccines protect from active TB but new vaccines are required to protect against pulmonary disease and infection. Recent advances in post-genomics technologies have allowed the characterization of host-pathogen interactions to discover new protective antigens and mechanisms to develop more effective vaccines against TB. Studies in the wild boar model resulted in the identification of complement component 3 (C3) as a natural correlate of protection against TB. Oral immunization with heat-inactivated mycobacteria protected wild boar against TB and showed that C3 plays a central role in protection. These results point at C3 as a target to develop novel vaccine formulations for more effective protection against TB in humans and animals. | - |
dc.description.sponsorship | Funding for TB research was obtained from grants AGL2014-56305 (Ministry of Economy, Spain and FEDER) and European Union FP7 WildTBvac No. 613779. | - |
dc.publisher | Taylor & Francis | - |
dc.relation | info:eu-repo/grantAgreement/EC/FP7/613779 | - |
dc.relation | info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/AGL2014-56305-C3-1-R | - |
dc.rights | closedAccess | - |
dc.subject | Mycobacteria | - |
dc.subject | Vaccine | - |
dc.subject | Immunology | - |
dc.subject | Complement | - |
dc.subject | Tuberculosis | - |
dc.title | Complement component 3: a new paradigm in tuberculosis vaccine | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1586/14760584.2016.1125294 | - |
dc.date.updated | 2019-01-11T09:58:34Z | - |
dc.description.version | Peer Reviewed | - |
dc.language.rfc3066 | eng | - |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | - |
dc.contributor.funder | European Commission | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100003329 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.pmid | 26605515 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.openairetype | artículo | - |
Aparece en las colecciones: | (IREC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
9
checked on 11-abr-2024
SCOPUSTM
Citations
14
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
13
checked on 29-feb-2024
Page view(s)
183
checked on 23-abr-2024
Download(s)
59
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.